EKF DIAGNOSTICS HOLDINGS PLC EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that the Board of EKF has been informed that on Friday 1 October, 2021, certain funds connected to Christopher Mills, Non-executive Chairman, sold a total of 1,275,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 84.0 pence per Ordinary Share.
Following this transaction, Christopher Mills' total direct and indirect interest in the Company is 130,875,000 Ordinary Shares, representing approximately 28.76% of the total voting rights over the Company's issued share capital.
The Notification of Dealing Form required in accordance with UK MAR is set out below and reflects the sale of 637,500 Ordinary Shares by each of the North Atlantic Smaller Companies Investment Trust plc ("NASCIT") and the Oryx International Growth Fund Limited ("Oryx").
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | Christopher Mills | |||
2 | Reason for the notification | ||||
a) | Position/status | Christopher Mills is Non-executive Chairman of the Company. Mr. Mills is a partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to NASCIT. Mr Mills is also a director of Harwood Capital Management (Gibraltar) Limited, which is Investment Manager and Investment Adviser to Oryx. | |||
b) | Initial notification /Amendment | Initial Notification | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | EKF Diagnostics Holdings plc | |||
b) | LEI | 213800DXTF3EAUK1AR05 | |||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
Identification code | GB0031509804 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
£0.84 | 637,500 | ||||
£0.84 | 637,500 | ||||
d) | Aggregated information | ||||
- Aggregated volume | 1,275,000 | ||||
- Price | £0.84 | ||||
e) | Date of the transaction | 1 October 2021 | |||
f) | Place of the transaction | London Stock Exchange | |||
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | ||
Christopher Mills, Non-executive Chairman | Tel: +44 (0)29 2071 0570 | ||
Mike Salter, CEO | |||
Richard Evans, FD & COO | |||
Singer Capital Markets (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7496 3000 | ||
Aubrey Powell / George Tzimas / Tom Salvesen | |||
Investec Bank plc (Joint Broker) | Tel: +44 (0)20 7597 4000 | ||
Gary Clarence / Daniel Adams | |||
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or | ||
Paul McManus / Lianne Cawthorne | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 | ||
Attachments
- Original document
- Permalink
Disclaimer
EKF Diagnostics Holdings plc published this content on 05 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 October 2021 15:18:07 UTC.
